CALGARY, Nov. 1 /CNW/ - Dr. Brad Thompson, President and CEO of
Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will present a corporate
overview of the Company at the Acumen BioFin Rodman & Renshaw 9th Annual
Healthcare Conference on Tuesday, November 6, 2007 at 3:20 p.m. ET. The event
will be held at the New York Palace Hotel from November 5-7, 2007.
A live audio webcast of the presentation will be available at:
http://www.wsw.com/webcast/rrshq12/oncy/ or on the company's website at
www.oncolyticsbiotech.com. It is recommended that listeners log on 15 minutes
in advance of the presentation to register and download any necessary
An audio replay will be accessible following the presentation at
About Oncolytics Biotech Inc.
Oncolytics is a Calgary-based biotechnology company focused on the
development of oncolytic viruses as potential cancer therapeutics. Oncolytics'
clinical program includes a variety of Phase I and Phase II human trials using
REOLYSIN®, its proprietary formulation of the human reovirus, alone and in
combination with radiation or chemotherapy. For further information about
Oncolytics, please visit www.oncolyticsbiotech.com
The presentation and webcast times are subject to change. This release
and the presentation related thereto contain forward-looking statements which
involve known and unknown risks, delays, uncertainties and other factors not
under the Company's control and which may cause actual results, performance or
achievements of the Company to be materially different from the results,
performance or expectations implied by these forward-looking statements. Such
risks and uncertainties include, among others, the efficacy of REOLYSIN® as
a cancer treatment, the success and timely completion of clinical studies and
trials, uncertainties related to the research and development of
pharmaceuticals and uncertainties related to the regulatory process. Investors
should consult the Company's quarterly and annual filings with the Canadian
and U.S. securities commissions for additional information on risks and
uncertainties relating to the forward-looking statements. Investors are
cautioned against placing undue reliance on forward-looking statements. The
Company does not undertake to update these forward- looking statements.